Special Issue "Apoptosis and Autophagy: 2nd Edition"

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Cell Biology and Tissue Engineering".

Deadline for manuscript submissions: closed (9 June 2023) | Viewed by 1031

Special Issue Editor

Department of Visceral Thoracic and Vascular Surgery, Philipps University Marburg, Baldingerstrasse, 35043 Marburg, Germany
Interests: cell death; autophagy; solid cancer; neuro-endocrine; epigenetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The first volume of the Special Issue “Apoptosis and Autophagy” (https://www.mdpi.com/journal/life/special_issues/apoptosis_and_autophagy) was an success, and it is our pleasure to announce the second volume.

Apoptosis and autophagy represent two fundamental cellular processes. They are involved in cell fate decision and they crosstalk with each other through the involvement of different key players. Nonetheless, the ability of apoptosis to cause cell death is counterbalanced by its ability to inhibit the cell death mediated by autophagy. Autophagy can also inhibit apoptosis and cause cell death. The intimate crosstalk between apoptosis and autophagy has not yet been explored. It can occur during embryogenesis, tissue development, cell maturation and senescence. Alterations in these intriguing mechanisms can occur during tumorigenesis and other pathologies in mammals. Further evidence is urgently needed to clarify these fine-tuned cellular processes.    

This Special Issue of Life focuses on the recent advances in apoptosis and autophagy. We look forward to your submissions.

Dr. Pietro Di Fazio
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • crosstalk between apoptosis and autophagy
  • apoptosis/autophagy and tumorigenesis
  • impairment of cell death in cancer
  • targeting
  • natural compounds
  • epigenetics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 2705 KiB  
Article
Anti-Proliferative Effect of Radiotherapy and Implication of Immunotherapy in Anaplastic Thyroid Cancer Cells
Life 2023, 13(6), 1397; https://doi.org/10.3390/life13061397 - 15 Jun 2023
Cited by 1 | Viewed by 880
Abstract
Radiotherapy and immunotherapy have shown promising efficacy for the treatment of solid malignancies. Here, we aim to clarify the potential of a combined application of radiotherapy and programmed cell death-ligand 1 (PD-L1) monoclonal antibody atezolizumab in primary anaplastic thyroid cancer (ATC) cells. The [...] Read more.
Radiotherapy and immunotherapy have shown promising efficacy for the treatment of solid malignancies. Here, we aim to clarify the potential of a combined application of radiotherapy and programmed cell death-ligand 1 (PD-L1) monoclonal antibody atezolizumab in primary anaplastic thyroid cancer (ATC) cells. The radiation caused a significant reduction in cell proliferation, measured by luminescence, and of the number of colonies. The addition of atezolizumab caused a further reduction in cell proliferation of the irradiated ATC cells. However, the combined treatment did not cause either the exposure of the phosphatidylserine or the necrosis, assessed by luminescence/fluorescence. Additionally, a reduction in both uncleaved and cleaved forms of caspases 8 and 3 proteins was detectable in radiated cells. The DNA damage evidenced the over-expression of TP53, CDKN1A and CDKN1B transcripts detected by RT-qPCR and the increase in the protein level of P-γH2AX and the DNA repair deputed kinases. PD-L1 protein level increased in ATC cells after radiation. Radiotherapy caused the reduction in cell viability and an increase of PD-L1-expression, but not apoptotic cell death in ATC cells. The further combination with the immunotherapeutic atezolizumab could increase the efficacy of radiotherapy in terms of reduction in cell proliferation. Further analysis of the involvement of alternative cell death mechanisms is necessary to clarify their cell demise mechanism of action. Their efficacy represents a promising therapy for patients affected by ATC. Full article
(This article belongs to the Special Issue Apoptosis and Autophagy: 2nd Edition)
Show Figures

Figure 1

Back to TopTop